Relationship between level of circulating modified LDL and the extent of coronary artery disease in type 2 diabetic patients

British Journal of Biomedical Science

Volumn 64, Issue 3, 2007, Pages 109-116

  El Bassiouni, E A ^a   Helmy, M H ^a   El Zoghby, S M ^a   El Nabi Kamel, Maher Abd ^a   Hosny, R M ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Coronary artery disease; Diabetes mellitus; Lipoprotein, low density

Indexed keywords

ANTIDIABETIC AGENT; CHLORPROPAMIDE; FREE RADICAL; GLIBENCLAMIDE; GLUCOSE; GLUTATHIONE; LOW DENSITY LIPOPROTEIN; METFORMIN;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIABETIC PATIENT; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INTIMA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TUNICA MEDIA; VASCULAR DISEASE;

EID: 34748816789     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2007.11732768     Document Type: Article

References (47)

1. Sherwin RS. Diabetes mellitus. In: Bennett JC, Plum F eds. Cecil's textbook of medicine 20th edn. Philadelphia: Saunders, 1996: 1258-77.
2. Haffner SM; American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 2003; 26: S83-S86.
3. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-12.
4. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
5. Jessup W, Kritharides L. Metabolism of oxidized LDL in the macrophages. Curr Opin Lipidol 2000; 11: 473-81.
6. Chen CH, Jiang W, Via DP et al. Oxidized low density lipoprotein inhibit endothelial cell proliferation by suppressing basic fibroblast growth factor expression. Circulation 2000; 101: 171-7.
7. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 1969; 6: 24-7.
8. Karl J. Development and standardization of a new immunoturbidimetric HbA1c Assay. Klin Lab 1993; 39: 991-6.
9. Buccolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973; 19: 476-82.
10. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total cholesterol. Clin Chem 1974; 20: 470-5.
11. Albers JJ, Warmick GR, Cheny MC. Determination of HDL-C. Lipids 1978; 13: 926-32.
12. Steinmetz J, Tarallo P, Fournier B, Caces E, Siest G. Reference limits of apolipoprotein A-I and apolipoprotein B using an IFCC standardized immunonephelometric method. Eur J Clin Chem Clin Biochem 1995; 33: 337.
13. Holvoet P, Mertens A, Verhamme P et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001; 21: 844-8.
14. Inoue T. Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease. J Am Coll Cardiol 2001; 37: 775-9.
15. Scoccia AE, Molinuevo MS, McCarthy AD, Cortizo AM. A simple method to assess the oxidative susceptibility of low density lipoproteins. BMC Clin Pathol 2001; 1: 1-6.
16. Draper HH, Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol 1990; 186: 421-31.
17. Griffith OW. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinyl pyridine. Anal Biochem 1980; 106: 207-12.
18. Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 2001; 30: 1191-212.
19. Sundram RK, Bhaskar A, Vijayalingam S, Viswanathan M, Mohan R, Shanmugasun-Daram KR. Antioxidant status and lipid peroxidation in type II diabetes mellitus with and without complications. Clin Sci 1996; 90: 255-60.
20. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19: 257-67.
21. Lu SC. Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB J 1999; 13: 1169-83.
22. Samiec PS, Drews-Botsch C, Flagg EW et al. Glutathione in human plasma: decline in association with aging, age-related macular degeneration, and diabetes. Free Radic Biol Med 1998; 24: 699-704.
23. Vijayalingam S, Parthiban A, Shanmugasundaram KR, Mohan V. Abnormal antioxidant status in impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabetic Med 1996; 13: 715-9.
24. Dieber-Rotheneder M, Puhl H, Waeg G, Striegl G, Esterbaur H. Effect of oral supplementation with D-tocopherol on the vitamin E content of human low density lipoproteins and resistance to oxidation. J Lipid Res 1991; 32: 1325-32.
25. Porkkala-Sarataho E, Nyyssnen K, Salonen JT. Increased oxidation resistance of atherogenic plasma lipoproteins at high vitamin E levels in non-vitamin E supplemented men. Atherosclerosis 1996; 124: 83-94.
26. Freisleben H, Packer L. Free radical scavenging activities, interactions and recycling of antioxidants. Biochem Soc Trans 1993; 21: 325-30.
27. Jain SK, Mc Vie R, Smith T. Vitamin E supplementation restores glutathione and malondialdehyde to normal concentrations in erythrocytes of type 1 diabetic children. Diabetes Care 2000; 23: 1389-94.
28. Laakso M, Lehto S, Penttila I, Pyorala K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993; 88: 1421-30.
29. Goldberg IJ. Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab 2001; 86: 965-71.
30. Lamarche B, Tchernof A, Mauriège P et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279: 1955-61.
31. Wagner AM, Perez A, Calvo F, Bonet R, Castellvi A, Ordonez J. Apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients. Diabetes Care 1999; 22: 812-7.
32. Hegele RA, Harris SB, Zinman B, Hanley AJ, Connelly PW. Increased plasma apo-lipoprotein B-containing lipoproteins associated with increased urinary albumin within the microalbuminuria range in type 2 diabetes. Clin Biochem 1999; 32: 143-8.
33. Steinberg D. Oxidative modification of LDL and atherogenesis. Circulation 1997; 95: 1062-71.
34. Mabile L, Meihac O, Escargueil-Blanc I et al. Mitochondrial function is involved in LDL oxidation mediated by human cultured endothelail cells. Arterioscler Thromb Vasc Biol 1997; 17: 1575-82.
35. Holvoet P, Vanhaecke J, Janssens S. Oxidized LDL and malondialdehyde- modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998; 98: 1487-94.
36. Shimada K, Mokuno H, Matsunaga E et al. Predictive value of circulating oxidized LDL for cardiac events in type 2 diabetic patients with coronary artery disease. Diabetes Care 2004; 27: 843-4.
37. Simons PC, Algra A, Bots ML, Grobbee DE, van der Graaf Y. Common carotid intima-media thickness and arterial stiffness: indicators of cardiovascular risk in high-risk patients. The SMART Study (Second Manifestations of ARTerial Disease). Circulation 1999; 100: 951-7.
38. O'Leary D, Polak J, Kronmal R, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340: 14-22.
39. Salonen JT, Yla-Herttuala S, Yamamoto R et al. Autoantibodies against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883-7.
40. Mironova MA, Klein RL, Virella GT, Lopes-Virella MF. Anti-modified LDL antibodies, LDL-containing immune complexes and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes. Diabetes 2000; 49: 1033-41.
41. Anderson JW, Gowri MS, Turner J et al. Antioxidant supplementation effects on low-density lipoprotein oxidation for individuals with type 2 diabetes mellitus. J Am Col Nutr 1999; 18: 451-61.
42. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett W. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328: 1450-6.
43. Fuller CJ, Chandalia M, Garg A, Grundy SM, Jialal I. RRR-alpha-tocopherol acetate supplementation at pharmacological doses decreases low-density- lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus. Am J Clin Nutr 1996; 63: 753-9.
44. May JM. Is ascorbic acid an antioxidant for the plasma membrane? FASEB J 1999; 13: 995-1006.
45. Upston JM, Terentis AC, Stocker R. Tocopherol-mediated peroxidation of lipoproteins: implications for vitamin E as a potential antiatherogenic supplement. FASEB J 1999; 13: 977-94.
46. Carr AC, Tijerina T, Frei B. Vitamin C protects against and reverses specific hypochlorous acid- and chloramine-dependent modifications of low-density lipoprotein. Biochem J 2000; 346: 491-9.
47. Faure P. Protective effects of antioxidant micronutrients (vitamin E, zinc and selenium) in type 2 diabetes mellitus. Clin Chem Lab Med 2003; 41: 995-8.